While Novartis combats generic onslaught in the courts, FDA approves first Gilenya copycats

While Novartis is battling to weaken the challengers vying to market copycat versions of its blockbuster multiple sclerosis treatment Gilenya — the US drug regulator on Thursday approved a trifecta of the drug’s first knockoffs. When they will launch is another question altogether.